Vaxent is an early stage vaccine development company located in Memphis. The Company's lead product in development is a subunit vaccine against group A streptococcus which has been tested in early stage human clinical trials. Vaxent plans to use its core competency in protein vaccine technology to advance its lead product in clinical testing, as well as develop other new vaccines against infectious diseases.
"Innova has been instrumental in the founding and development of Vaxent. We simply would not be where we are today without the financial and strategic support of Innova. Innova has brought more than money to the table for Vaxent, as Ken and his team have been involved in creating our business plan. We are in some important partnering negotiations and Innova's support has been critical."
--Todd Patrick, CEO